• Medicus Pharma won UAE Department of Health IND clearance to start the PRECISION-E2 Phase 2a Teverelix study in moderate-to-severe endometriosis.
• Regulators completed a review spanning CMC, non-clinical, clinical, safety data; trial start now hinges on site IRB, ethics sign-offs.
• Placebo-controlled study targets about 84 women across UAE sites; primary endpoint is maintaining estradiol in the 20-50 pg/mL range for 14 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310730PRIMZONEFULLFEED9801287) on July 31, 2026, and is solely responsible for the information contained therein.